普萊柯(603566.SH):擬投建獸用滅活疫苗生產項目、生物製品車間及配套設施項目
格隆匯9月23日丨普萊柯(603566.SH)公佈,高致病性禽流感是農業農村部規定的一類動物疫病,是國家動物疫病強制免疫計劃規定的免疫病種之一。公司全資子公司普萊柯(南京)生物技術有限公司系國家高致病性禽流感疫苗定點生產企業,為解決現有產能瓶頸問題,擬由其全資子公司普萊柯(南京)生物工程有限公司(“普萊柯南京”)投資4億元建設年產能20億毫升獸用滅活疫苗生產基地,用於生產高致病性禽流感疫苗產品。
根據《獸藥生產質量管理規範(2020年修訂)》(“新版獸藥GMP”)規定,所有獸藥生產企業均應在2022年6月1日前達到新版獸藥GMP要求,因此,子公司洛陽惠中生物技術有限公司(“惠中生物”)擬按照新版獸藥GMP要求對現有生產線進行升級改造,並提升現有生產線產能和自動化水平;同時新建細菌滅活疫苗生產線,以滿足日益增加的市場需求。
隨着公司寵物用產品陸續研發成功,為滿足未來生產需求,惠中生物將新建部分寵物疫苗產品生產線,以實現狂犬病滅活疫苗及犬瘟熱、犬細小二聯活疫苗等產品的規模化生產,保證寵物疫苗的供給。
此次投資項目涉及高致病性禽流感、寵物相關疫苗產品線建設,系落實公司發展戰略、促進公司長期可持續發展的重要投資;對現有疫苗生產線按照新版獸藥GMP 標準進行提升改造,是順應行業發展趨勢,全面優化提升產品質量的必要投資行為。短期而言,可能會對公司現金流造成一定壓力,但長期來看,上述投資項目實施可進一步增強公司核心競爭力,符合公司的發展戰略和長期規劃,將會為公司未來業績產生積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.